Chinese SLE Treatment and Research Group Registry (CSTAR) XIII: prevalence and risk factors for chronic scarring alopecia in patients with systemic lupus erythematosus
机构：[1]Department of Rheumatology, State Key Laboratory of Complex Severe andRare Diseases, National Clinical Research Center for Dermatologic andImmunologic Diseases (NCRC-DID), Key Laboratory of Rheumatology andClinical Immunology, Peking Union Medical College Hospital, ChineseAcademy of Medical Science and Peking Union Medical College, No.1 Shuaifuyuan, Wangfujing Ave, Beijing 100730, China[2]Department ofRheumatology, Xiangya Hospital, Central South University, Changsha, China[3]Department of Epidemiology and Bio-statistics, Institute of Basic MedicalSciences, China Academy of Medical Sciences & Peking Union MedicalCollege, Beijing, China[4]Department of Rheumatology, The Second AffiliatedHospital of Nanchang University, Nanchang, China[5]Department ofRheumatology and Clinical Immunology, The First Affiliated Hospital ofGuangxi Medical University, Nanning, China[6]Department of Rheumatology,Hainan General Hospital, Haikou, China[7]Department of Clinical Immunologyand Rheumatology, Xijing Hospital Affiliated to the Fourth Military MedicalUniversity, Xi’an, China[8]Department of Rheumatology, Affiliated Hospital ofInner Mongolia Medical College, Hohhot, China[9]Department ofRheumatology and Immunology, Nanfang Hospital, Southern MedicalUniversity, Guangzhou, China[10]Department of Rheumatology, First AffiliatedHospital of Kunming Medical University, Kunming, China昆明医科大学附属第一医院[11]Department ofRheumatology, Tianjin Medical University General Hospital, Tianjin, China[12]Department of Rheumatology, People Hospital of Xinjiang UygurAutonomous Region, Urumchi, China
BackgroundScarring alopecia in systemic lupus erythematosus (SLE) patients caused reduced life quality and prolonged disease course. This case-control study aims to survey the prevalence of scarring alopecia during the disease course of SLE and evaluate the risk factors for scarring alopecia in Chinese SLE patients.MethodsSLE patients in Chinese SLE treatment and Research group (CSTAR) were recruited. Scarring alopecia was defined according to SLICC/ACR-DI which was collected during follow-up visits or via self-reported questionnaires. We collected demographic characteristics, common comorbidities, autoantibody profiles, disease activity status, major organ involvements, and treatment strategies of these patients at registry. Univariate and multivariate logistic regression analyses were used to investigate the risk factors for scarring alopecia.ResultsWe recruited 4792 SLE patients, and 374 (7.80%) patients had scarring alopecia. Mucocutaneous lesions (OR 2.062, p <0.001), high SLICC/ACR-DI (OR 1.409, p <0.001), and positive anti-Sm (OR 1.374, p =0.029) were risk factors for scarring alopecia, while renal (OR 0.714, p =0.028) and cardio-respiratory involvements (OR 0.347, p =0.044), and immunosuppressant treatment (OR 0.675, p <0.001) were significantly negative associated with it.ConclusionsThe prevalence of scarring alopecia in SLE patients is 7.80%. Active treatment strategies should be adopted to prevent scarring alopecia occurring.
基金：
Chinese National Key Technology R&D Program, Ministry of Science and Technology [2017YFC0907601, 2017YFC0907602, 2016YFC0901500]; CAMS Innovation Fund for Medical Sciences (CIFMS) [2019-I2M-2008]; Fundamental Research Funds for the Central UniversitiesFundamental Research Funds for the Central Universities [3332018039]
第一作者机构：[1]Department of Rheumatology, State Key Laboratory of Complex Severe andRare Diseases, National Clinical Research Center for Dermatologic andImmunologic Diseases (NCRC-DID), Key Laboratory of Rheumatology andClinical Immunology, Peking Union Medical College Hospital, ChineseAcademy of Medical Science and Peking Union Medical College, No.1 Shuaifuyuan, Wangfujing Ave, Beijing 100730, China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Yirong Xiang,Mengtao Li,Hui Luo,et al.Chinese SLE Treatment and Research Group Registry (CSTAR) XIII: prevalence and risk factors for chronic scarring alopecia in patients with systemic lupus erythematosus[J].ARTHRITIS RESEARCH & THERAPY.2021,23(1):doi:10.1186/s13075-020-02407-5.
APA：
Yirong Xiang,Mengtao Li,Hui Luo,Yanhong Wang,Xinwang Duan...&Xiaofeng Zeng.(2021).Chinese SLE Treatment and Research Group Registry (CSTAR) XIII: prevalence and risk factors for chronic scarring alopecia in patients with systemic lupus erythematosus.ARTHRITIS RESEARCH & THERAPY,23,(1)
MLA：
Yirong Xiang,et al."Chinese SLE Treatment and Research Group Registry (CSTAR) XIII: prevalence and risk factors for chronic scarring alopecia in patients with systemic lupus erythematosus".ARTHRITIS RESEARCH & THERAPY 23..1(2021)
医学